Memorial Sloan Kettering Cancer Center
New York, NY, USA
Dr. Feldman is the Section Head for Germ Cell Cancer within the Genitourinary Oncology Service and an Associate Attending Physician on the Genitourinary Oncology Service and Bone Marrow Transplant (BMT) Service within the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSKCC). He is also an Associate Professor in Medicine at Weill Medical College of Cornell University, both in New York City, NY.
He completed his Internal Medicine residency at New York University before serving as chief resident for the Department of Medicine at MSKCC, where he went on to complete fellowship in medical oncology and hematology.
Dr. Feldman’s research focuses on understanding the biology and improving the treatment for patients with germ cell tumors (GCT) and kidney tumors. He is also interested in the mechanism and management of late toxicities resulting from GCT treatment, particularly effects on the cardiovascular system.He has led and is currently leading national and international trials in the treatment of GCT and kidney cancer and has presented his research at meetings around the world.
Dr. Feldman is the recipient of several awards including the John Mendelsohn Teaching Award and the Paul Sherlock Housestaff Teaching Award for the Department of Medicine at MSKCC and has been recognized in New York Magazine’s Top Doctors in New York City. He has also received several research grants including an ASCO Conquer Cancer Foundation Young Investigator Award, an Aflac / Children’s Oncology Group Adolescent and Young Adult Biology Research Grant, a Movember GAP5 award, and a Cycle for Survival award. Dr. Feldman has published more than 125 peer-reviewed publications on urologic malignancies and authored review chapters in several prominent text books including Harrison’s Principles of Internal Medicine, DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology, and the Comprehensive Textbook of Genitourinary Oncology.
Disclosure information not submitted.